ES2320743T3 - Mutantes de quimiocina que actuan como antagonistas de quimiocinas. - Google Patents

Mutantes de quimiocina que actuan como antagonistas de quimiocinas. Download PDF

Info

Publication number
ES2320743T3
ES2320743T3 ES02791832T ES02791832T ES2320743T3 ES 2320743 T3 ES2320743 T3 ES 2320743T3 ES 02791832 T ES02791832 T ES 02791832T ES 02791832 T ES02791832 T ES 02791832T ES 2320743 T3 ES2320743 T3 ES 2320743T3
Authority
ES
Spain
Prior art keywords
baselineskip
chemokine
rantes
mutants
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02791832T
Other languages
English (en)
Spanish (es)
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Jeffrey Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of ES2320743T3 publication Critical patent/ES2320743T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES02791832T 2001-12-17 2002-12-16 Mutantes de quimiocina que actuan como antagonistas de quimiocinas. Expired - Lifetime ES2320743T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000761 2001-12-17
EP01000761 2001-12-17

Publications (1)

Publication Number Publication Date
ES2320743T3 true ES2320743T3 (es) 2009-05-28

Family

ID=8176112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02791832T Expired - Lifetime ES2320743T3 (es) 2001-12-17 2002-12-16 Mutantes de quimiocina que actuan como antagonistas de quimiocinas.

Country Status (10)

Country Link
US (1) US7553483B2 (enExample)
EP (1) EP1458756B1 (enExample)
JP (1) JP2005525089A (enExample)
AT (1) ATE421974T1 (enExample)
AU (1) AU2002358144B2 (enExample)
CA (1) CA2468790A1 (enExample)
DE (1) DE60231057D1 (enExample)
ES (1) ES2320743T3 (enExample)
IL (1) IL162600A0 (enExample)
WO (1) WO2003051921A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305573T3 (es) * 2002-12-23 2008-11-01 Laboratoires Serono Sa Uso de metantes de quimiocinas cc ccl5/rantes contra transtornos del higado.
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2380975A1 (de) * 2010-04-22 2011-10-26 Scil Proteins GmbH Verfahren zur Herstellung von rekombinantem Thrombin
US9352000B2 (en) * 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
EP3307330B1 (en) * 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
WO2017077062A1 (en) * 2015-11-05 2017-05-11 Ludwig-Maximilians-Universität München A peptide derived from human neutrophile peptide 1
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
JP2024536368A (ja) 2021-10-06 2024-10-04 ヴァイロセラ リミテッド 新規免疫調節因子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679436B2 (en) 1991-12-23 1997-07-03 British Bio-Technology Limited Stem cell inhibiting proteins
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
AU5137698A (en) 1996-12-05 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Novel dna, novel protein, and novel antibody
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
EP1040191B1 (en) 1997-12-23 2005-11-02 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
JPH11243960A (ja) 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトｃｃ型ケモカインエオタキシン３
EP1098664B1 (en) * 1998-07-22 2003-08-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
AU5617900A (en) * 1999-06-17 2001-01-09 Robert C. Gallo Chimeric chemokine-antigen polypeptides and uses therefor
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis

Also Published As

Publication number Publication date
JP2005525089A (ja) 2005-08-25
EP1458756A1 (en) 2004-09-22
AU2002358144A1 (en) 2003-06-30
DE60231057D1 (de) 2009-03-19
ATE421974T1 (de) 2009-02-15
EP1458756B1 (en) 2009-01-28
US20050220757A1 (en) 2005-10-06
WO2003051921A1 (en) 2003-06-26
CA2468790A1 (en) 2003-06-26
US7553483B2 (en) 2009-06-30
IL162600A0 (en) 2005-11-20
AU2002358144B2 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
ES2320743T3 (es) Mutantes de quimiocina que actuan como antagonistas de quimiocinas.
ES2282666T3 (es) Antagonistas de quimiocinas cxc de union a cxcr3.
US7425324B2 (en) Antagonists of MCP proteins
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
US6709649B1 (en) RANTES derived peptides with anti-HIV activity
JP2011501675A (ja) Ｓｄｆ−１を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法
ES2254938T3 (es) Mutantes de quimioquinas que poseen biodisponibilidad oral mejorada.
EP1673388B1 (en) Cxcl8 antagonists
US20080299072A1 (en) Chemokine Antagonists
WO2008015199A1 (en) Chemokine antagonists
WO2005056581A2 (en) Peptide able to specifically bind a chemokine receptor and use thereof